Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

Colin Phipps, MBBS, MRCP, FRCPath, Yuh Shan Lee, MBBS, MRCP, FRCPath, Chandramouli Nagarajan, MBBS, MD MRCP, Yunxin Chen, MBBS, MRCP, FRCPath, Allan ZK Goh, Lay Poh Khoo, BSc, Kevin Tay, MD, Miriam Tao, MD, Richard Quek, Tiffany Tang, MD, Mohamad Farid, MD, Soon Thye Lim, MBBS, MRCP, Sathish Kumar Gopalakrishnan, FRCPath, Nicholas F Grigoropoulos, MRCP, FRCPath, Yvonne Loh, MBBS, MRCP, Daryl Tan, MBBS, MRCP, William YK Hwang, MBBS, MRCP, FRCP, Yeow Tee Goh, MD

Blood (2016) 128 (22): 1871.

https://doi.org/10.1182/blood.V128.22.1871.1871

Published: 2016

Journal Articles

In Vitro Expanded γδ T Cells Derived from Cord Blood Induce Potent and Specific Cytotoxicity Against Human Acute Myeloid Leukemia Cells

Alice MS Cheung, PhD, Kar Wai Tan, PhD, Dian Yan Guo, BSc, Su-Ann Goh, BSc, Amanda SY Lau, BSc, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, MRCP, FRCP, Yeow Tee Goh, MD, Shang Li, MD PhD

Blood (2016) 128 (22): 2168.

https://doi.org/10.1182/blood.V128.22.2168.2168

Published: 2016

Journal Articles

A Case of Two Young Brothers with Natural-Killer/T-Cell Lymphoma

Tiffany Tang, MD, Maarja-Liisa Nairismagi, PhD, Alvin Yu Jin Ng, PhD, Byrappa Venkatesh, Joanne Ngeow, MD, Shao-Tzu Li, Yurike Laurensia, BSc, Jing Quan Lim, PhD, Sanjanaa Nagarajan, MSc, Burton Chia, Jing Tan, PhD, Yeow Tee Goh, MD, Miriam Tao, MD, Richard Hong Hui Quek, MD, Mohamad Farid, MD, Soon Thye Lim, MD, Choon Kiat Ong

Blood (2016) 128 (22): 5293.

https://doi.org/10.1182/blood.V128.22.5293.5293

Published: 2016

Journal Articles

Predictors of Delayed Clearance and Toxicities from High Dose Methotrexate in Patients Receiving Hypercvad Regimen for Treatment of Lymphoid Malignancies

Hong Yen Ng, MSc, Pei Shi Ong, PhD, Xue Ming Loy, BSc, Yufei Chen, BSc, Yeow Tee Goh, MD

Blood (2016) 128 (22): 1630.

https://doi.org/10.1182/blood.V128.22.1630.1630

Published: 2016

Journal Articles

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Marc S Raab, MD, Enrique M. Ocio, Sheeba K. Thomas, M.D., Andreas Günther, Daniel Lebovic, MD, Shaji K Kumar, MD, Andrzej J. Jakubowiak, MD, PhD, Dongweon Song, Fang Xiang, David Hynds, K. Gary Vanasse, M.D., Yeow Tee Goh, MD

Blood (2013) 122 (21): 3186.

https://doi.org/10.1182/blood.V122.21.3186.3186

Published: 2013

Journal Articles

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response

Daryl Tan, MD, William YK Hwang, MBBS, FRCP, FAMS, Colin Phipps Diong, Wee Lee Goh, BSC, Lionel K.Y See, BSc, Yiong Huak Chan, PHD, Soon Thye Lim, MRCP MBBS, Soo Chin Ng, MBBS MRCP, S Fadilah, MBBS, Soo-Yong Tan, MBBS, FRCPath, DPhil, Won Seog Kim, MD, Yeow Tee Goh, MD

Blood (2012) 120 (21): 3669.

https://doi.org/10.1182/blood.V120.21.3669.3669

Published: 2012

Journal Articles

Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response

Daryl Tan, MBBS, MRCP, Bernard K.C Yap, BSc, Lionel K.Y See, BSc, Grace Kam, MBBS, MRCP, Colin Phipps Diong, Yuh Shan Lee, MBBS, MRCP, Dawn Mya, MBBS, MRCP, William Hwang, MBBS, FRCP, FAMS, Yeow Tee Goh, MD

Blood (2010) 116 (21): 3056.

https://doi.org/10.1182/blood.V116.21.3056.3056

Published: 2010

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

Nina Wagner-Johnston, Andre Goy, MD, Tatyana Feldman, MD, Yeow Tee Goh, MD, Cheolwon Suh, MD, John William Sweetenham, MD, FRCP, Christine Powell, Sharon T. Sullivan, PhD, Erik R. Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2010) 116 (21): 2883.

https://doi.org/10.1182/blood.V116.21.2883.2883

Published: 2010

Journal Articles

Cytokine Induced Killer Cells Are Feasible and Safe for Both Autologous and Allogeneic Applications in Patients with Haematological Malignancies

Yeh Ching Linn, MD, Tsyr jong Lim, Madelaine Niam, Garnet Suck, PhD, Yeow Tee Goh, MD, William Hwang, Yvonne Loh, Lee Hui Ng, Hao Xiang Yong, Mickey Boon Chai Koh, MD, MRCP, MRCPath, PhD

Blood (2008) 112 (11): 2917.

https://doi.org/10.1182/blood.V112.11.2917.2917

Published: 2008

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Yeow Tee Goh, MD, Tamas Masszi, MD, PhD, Ricardo Pasquini, Frederic Maloisel, M. Brigid Bradley-Garelik, Chao Zhu, Herve Dombret, MD, PhD, FRCP

Blood (2008) 112 (11): 3226.

https://doi.org/10.1182/blood.V112.11.3226.3226

Published: 2008

NARROW

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

In Vitro Expanded γδ T Cells Derived from Cord Blood Induce Potent and Specific Cytotoxicity Against Human Acute Myeloid Leukemia Cells

A Case of Two Young Brothers with Natural-Killer/T-Cell Lymphoma

Predictors of Delayed Clearance and Toxicities from High Dose Methotrexate in Patients Receiving Hypercvad Regimen for Treatment of Lymphoid Malignancies

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response

Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

Cytokine Induced Killer Cells Are Feasible and Safe for Both Autologous and Allogeneic Applications in Patients with Haematological Malignancies

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only